Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function.

MLA

Zugazagoitia, Jon, et al. “Sorafenib for Non-Selected Patient Population with Advanced Hepatocellular Carcinoma: Efficacy and Safety Data According to Liver Function.” Clinical & Translational Oncology, vol. 15, no. 2, Feb. 2013, pp. 146–53. EBSCOhost, https://doi.org/10.1007/s12094-012-0902-3.

APA

Zugazagoitia, J., Manzano, A., Sastre, J., Ladero, J., Puente, J., & Díaz-Rubio, E. (2013). Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function. Clinical & Translational Oncology, 15(2), 146–153. https://doi.org/10.1007/s12094-012-0902-3

Chicago

Zugazagoitia, Jon, Aránzazu Manzano, Javier Sastre, Jose Ladero, Javier Puente, and Eduardo Díaz-Rubio. 2013. “Sorafenib for Non-Selected Patient Population with Advanced Hepatocellular Carcinoma: Efficacy and Safety Data According to Liver Function.” Clinical & Translational Oncology 15 (2): 146–53. doi:10.1007/s12094-012-0902-3.